Navigation Links
New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
Date:12/5/2009

el agents such as thalidomide, bortezomib, and lenalidomide. According to results from the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone (VISTA) trial, the combination of bortezomib, melphalan, and prednisone is significantly superior to melphalan and prednisone alone, which has been the current standard of care for multiple myeloma patients who cannot receive a stem cell transplant. However, research has not yet confirmed whether an alkylating agent (chemical compound) or an immunomodulatory therapy (drug that suppresses or stimulates the body's immune response) is the optimal partner for bortezomib. Researchers from the Spanish Myeloma Group designed a study to better determine if melphalan or thalidomide should be used as part of induction therapy (the initial treatment given to patients) in combination with bortezomib. The study showed that elderly patients were able to receive less aggressive treatment regimens of induction therapy by supplementing them with a maintenance treatment.

In order to evaluate whether the induction therapy regimen could be further optimized by decreasing toxicity while maintaining efficacy, the intensity of both treatment regimens was reduced as compared with the VISTA regimen, but supplemented with maintenance therapy. In this study, 260 patients with a median age of 75 years were randomized to receive a modified induction schedule of six cycles of bortezomib, melphalan, and prednisone (VMP) or bortezomib, thalidomide, and prednisone (VTP) as induction therapy followed by maintenance therapy with bortezomib and thalidomide (VT) or bortezomib and prednisone (VP) for up to three years.

Study results indicate that modified induction schedules for both VMP and VTP were highly effective with similar overall response rates (80 percent for VMP and 81 percent for VTP), which were determined using the European Group for Blood and Marrow Transplantation (EBMT) criteria
'/>"/>

SOURCE American Society of Hematology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that its ... its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With ... consumer goods industry, it can be difficult for companies to navigate, stay abreast ...
(Date:9/4/2015)... ... , ... “Getting away from the daily stressors and distractions of life may ... ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui at ... Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, has ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... Washington, DC (PRWEB) , ... September 04, 2015 ... ... dollar-wise they all pale in comparison to settlements under the Stark physician self-referral ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will ...
(Date:9/3/2015)... (PRWEB) , ... September 04, 2015 , ... AlignLife ... of September. , "There are so many children and adults who don't have ... says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those ...
Breaking Medicine News(10 mins):Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... Nov. 3 (HealthDay News) -- The rate of concussions among ... times higher than previously believed, and the issue needs to ... researchers warn. The study of 67 male ice-hockey players, ... during the 2009-2010 hockey season. During 52 games, 17 players ...
... TUESDAY, Nov. 2 (HealthDay News) -- One of the main ... symptoms in patients with early Alzheimer,s, although experts aren,t ruling ... the disease. The supplement, docosahexaenoic acid (DHA), is present ... it might play a role in treatment. But that ...
... report decreased pain and improved breathing following treatment of ... the therapy falls short of improving survival. Still, ... Cancer Center and presented today at the annual meeting ... BC, represents the first of its kind to document ...
... Birthdays Are Harder to Remember Than Others ( http://pss.sagepub.com/content/21/10/1525.abstract ... People may have a better memory for birthdays that ... birthdays tended to remember birthdays that were closer to ... their own birthday. In a separate experiment, after reading ...
... patients with the most common form of hepatitis C being ... hepatitis Cspecific protease inhibitor called telaprevir to the current standard ... cure) rate., The lead ... Ira M. Jacobson, chief of the Division of Gastroenterology and ...
... Serena Gordon HealthDay Reporter , TUESDAY, Nov. ... aren,t getting much-needed hospice care because the admission criteria ... cause of death in the U.S., and hospice care ... getting palliative [comfort] care is guidelines that try to ...
Cached Medicine News:Health News:Concussion Rate in Young Hockey Players Higher Than Thought 2Health News:Concussion Rate in Young Hockey Players Higher Than Thought 3Health News:Fish Oil Supplements May Not Slow Alzheimer's 2Health News:Fish Oil Supplements May Not Slow Alzheimer's 3Health News:Lombardi research: Robotic radiosurgery offers palliative care for hilar lung tumors 2Health News:New research from Psychological Science 2Health News:New research from Psychological Science 3Health News:New research from Psychological Science 4Health News:Hepatitis C study shows superior viral cure rate 2Health News:Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia 2Health News:Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia 3
(Date:9/4/2015)... Sept. 4, 2015  Allergan plc (NYSE: AGN ) ... Saunders , CEO and President of Allergan, will provide an ... Stanley Global Healthcare Conference 2015 in New York, ... The presentation will take place on Thursday, ... Grand Hyatt New York, 109 East 42nd Street, ...
(Date:9/4/2015)... , Sep. 04, 2015 Research ... the "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... used in the clinic under the trade name of Bondronat ... in 1996, sodium ibandronate was approved by the ... of osteoporosis under the trade name of Boniva. However, since ...
(Date:9/3/2015)... MUMBAI, India , Sept. 3, 2015  Cipla, ... to meet the everyday needs of all patients, today ... into definitive agreements to acquire two US-based companies, InvaGen ... subject to certain closing conditions, is valued at $550 ... combined revenue from these transactions is over $200 million ...
Breaking Medicine Technology:Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5
... March 31, 2011 Reportlinker.com announces that a ... catalogue: Molecular Diagnostics in ... http://www.reportlinker.com/p0368860/Molecular-Diagnostics-in-Infectious-Disease-Testing.html This TriMark Publications report ... diagnostics market known as molecular diagnostics testing for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Gout Therapeutics Market ... as Krystexxa, Uloric, Adenuric and Colcrys to ... Gout Therapeutics Market to ...
Cached Medicine Technology:Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 2Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 3Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 4Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 5Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 6Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 7Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 8Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 9Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 10Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 11Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 12Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 13Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 14Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 15Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 16Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 17Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing 18Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12